ReviewDiabetes technology & therapeutics2017
Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
Review in Diabetes technology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 204 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Are Todays Continuous Glucose Monitoring Precise and Can They be Used to Reveal and Reduce Glycaemic Variability?
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D
Impact of Continuous Glucose Monitoring (CGM) With Predictive Alarm for Hypoglycemia (Guardian Connect System) on Glycemic Control and Hypoglycemia Management in a Group of Adolescents With Type 1 Diabetes Mellitus Treated With Multiple Daily Insulin Injections (MDI).
Influence of Continuous Glucose Monitoring on Quality of Life in People With Type 2 Diabetes Mellitus
Who cites it
204 citing papers in PubMed, 3 syntheses or guidelines pooled it, 463 citations in OpenAlex.
- Impact of COVID-19 Lockdown on the Metabolic Control Parameters in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.Diabetes & metabolism journal · 2022Pooled it
- Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review.BMJ open diabetes research & care · 2022Pooled it
- Application and Utility of Continuous Glucose Monitoring in Pregnancy: A Systematic Review.Frontiers in endocrinology · 2019Pooled it
- Interactive Digital Visualization Counseling for Lifestyle Change in Patients at Risk of Cardiovascular Diseases: Randomized Controlled Trial.JMIR public health and surveillance · 2026Trial
- To assess the impact of individualized strategy and continuous glucose monitoring on glycemic control and mental health in pregnant women with diabetes.Frontiers in endocrinology · 2025Trial
- Exploring Decentralized Glucose and Behaviometric Monitoring of Persons with Type 2 Diabetes in the Setting of a Clinical Trial.Journal of diabetes science and technology · 2023Trial
- Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor.Journal of diabetes science and technology · 2022Trial
- Demonstrating the Clinical Impact of Continuous Glucose Monitoring Within an Integrated Healthcare Delivery System.Journal of diabetes science and technology · 2022Trial
- Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes.Journal of diabetes science and technology · 2020Trial
- Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Trial
- Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.Diabetes & vascular disease research · 2019Trial
- Noninvasive Interstitial Glucose Estimation Using Wearables and Machine Learning in Healthy Individuals and Individuals With Obesity: Observational Cohort Study.JMIR mHealth and uHealth · 2026Observational
- Continuous Molecular Monitoring Using Electrochemical Aptamer-Based Sensors: Remaining Challenges for Long-Term In Vivo Deployment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Impact of an Experience-Based Versus Traditional Continuous Glucose Monitoring Curriculum on Internal Medicine Resident Confidence and Knowledge.Journal of general internal medicine · 2026Article
- Beyond Diabetes: Continuous Glucose Monitoring as a Candidate Precision Tool for Cardiovascular Prevention and Healthy Longevity-A Hypothesis-Generating Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Use of continuous glucose monitoring (CGM) in diabetes management in Africa: opportunities, challenges, and future prospects.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Advances in Electrocardiogram-Based Non-Invasive Blood Glucose Monitoring Technology.Diabetes, obesity & metabolism · 2026Review
- Coronary plaque burden assessed by coronary CT angiography in individuals with type 1 diabetes and healthy controls.The international journal of cardiovascular imaging · 2026Article
- Noninvasive Detection of Acute Hyperglycemia Using Signal from Wearable ECG Sensors Considering Individual HRV Response Delays to Glucose.Biosensors · 2026Article
- Single-molecule readout of reversible nanoswitches enables continuous monitoring of low biomarker concentrations.Nature communications · 2026Article
144 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous Glucose Monitoring (CGM) has been demonstrated to be clinically valuable, reducing risks of hypoglycemia and hyperglycemia, glycemic variability (GV), and improving patient quality of life for a wide range of patient populations and clinical indications. Use of CGM can help reduce HbA1c and mean glucose. One CGM device, with accuracy (%MARD) of approximately 10%, has recently been approved for self-adjustment of insulin dosages (nonadjuvant use) and approved for reimbursement for therapeutic use in the United States. CGM had previously been used off-label for that purpose. CGM has been demonstrated to be clinically useful in both type 1 and type 2 diabetes for patients receiving a wide variety of treatment regimens. CGM is beneficial for people using either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). CGM is used both in retrospective (professional, masked) and real-time (personal, unmasked) modes: both approaches can be beneficial. When CGM is used to suspend insulin infusion when hypoglycemia is detected until glucose returns to a safe level (low-glucose suspend), there are benefits beyond sensor-augmented pump (SAP), with greater reduction in the risk of hypoglycemia. Predictive low-glucose suspend provides greater benefits in this regard. Closed-loop control with insulin provides further improvement in quality of glycemic control. A hybrid closed-loop system has recently been approved by the U.S. FDA. Closed-loop control using both insulin and glucagon can reduce risk of hypoglycemia even more. CGM facilitates rigorous evaluation of new forms of therapy, characterizing pharmacodynamics, assessing frequency and severity of hypo- and hyperglycemia, and characterizing several aspects of GV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.